Targeting nuclear RNA for in vivo correction of myotonic dystrophy
暂无分享,去创建一个
Bruce M. Wentworth | Charles A. Thornton | B. Wentworth | M. Nakamori | Seng H. Cheng | S. Pandey | T. M. Wheeler | C. Thornton | C. Bennett | A. Macleod | C. Frank Bennett | A. Leger | Thurman M. Wheeler | Andrew J. Leger | Sanjay K. Pandey | A. Robert MacLeod | Masayuki Nakamori | T. Wheeler | B. M. W. Are
[1] T. Cooper,et al. RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1 , 2012, Proceedings of the National Academy of Sciences.
[2] M. Nakamori,et al. Stabilization of expanded (CTG)•(CAG) repeats by antisense oligonucleotides. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[3] Bruce L. Miller,et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.
[4] Howard Y. Chang,et al. Long noncoding RNAs and human disease. , 2011, Trends in cell biology.
[5] M. Manoharan,et al. Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes , 2011, Nucleic acids research.
[6] M. Minczuk,et al. An Upstream Open Reading Frame and the Context of the Two AUG Codons Affect the Abundance of Mitochondrial and Nuclear RNase H1 , 2010, Molecular and Cellular Biology.
[7] N. Bonini,et al. Roles of trinucleotide-repeat RNA in neurological disease and degeneration , 2010, Trends in Neurosciences.
[8] Tyson A. Clark,et al. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy , 2010, Nature Structural &Molecular Biology.
[9] C. Bennett,et al. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. , 2010, Annual review of pharmacology and toxicology.
[10] B. Wieringa,et al. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy , 2009, Proceedings of the National Academy of Sciences.
[11] Krzysztof Sobczak,et al. Reversal of RNA Dominance by Displacement of Protein Sequestered on Triplet Repeat RNA , 2009, Science.
[12] M. Swanson,et al. Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. , 2009, Human molecular genetics.
[13] Heng Tao Shen,et al. Principal Component Analysis , 2009, Encyclopedia of Biometrics.
[14] David L. Spector,et al. 3′ End Processing of a Long Nuclear-Retained Noncoding RNA Yields a tRNA-like Cytoplasmic RNA , 2008, Cell.
[15] J. Lueck,et al. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. , 2007, Journal of Clinical Investigation.
[16] A. Munnich,et al. CTG Trinucleotide Repeat “Big Jumps”: Large Expansions, Small Mice , 2007, PLoS genetics.
[17] M. Swanson,et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. , 2006, Human molecular genetics.
[18] A. Rabinowitz,et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology , 2006, Nature Medicine.
[19] Michael Q. Zhang,et al. Regulating Gene Expression through RNA Nuclear Retention , 2005, Cell.
[20] H. Blum,et al. Translation of stable hepadnaviral mRNA cleavage fragments induced by the action of phosphorothioate-modified antisense oligodeoxynucleotides , 2005, Nucleic acids research.
[21] A. Briguet,et al. Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse , 2004, Neuromuscular Disorders.
[22] S. Crooke,et al. Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs* , 2004, Journal of Biological Chemistry.
[23] W. Hauswirth,et al. A Muscleblind Knockout Model for Myotonic Dystrophy , 2003, Science.
[24] G. Hardee,et al. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[25] D. L. Cole,et al. Solid Phase Synthesis of Phosphorothioate Oligonucleotides Utilizing Diethyldithiocarbonate Disulfide (DDD) as an Efficient Sulfur Transfer Reagent , 2003, Nucleosides, nucleotides & nucleic acids.
[26] C. F. Bennett,et al. Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents , 2003, The Journal of Biological Chemistry.
[27] S. Cannon,et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. , 2002, Molecular cell.
[28] A. Delacourte,et al. Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities. , 2001, Human molecular genetics.
[29] R. J. White,et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. , 2000, Science.
[30] B. Byrne,et al. Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophy , 2000, The EMBO journal.
[31] C. Junien,et al. Transgenic mice carrying large human genomic sequences with expanded CTG repeat mimic closely the DM CTG repeat intergenerational and somatic instability. , 2000, Human molecular genetics.
[32] T. Misteli,et al. Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides. , 2000, Nucleic acids research.
[33] Joshua M. Stuart,et al. MICROARRAY EXPERIMENTS : APPLICATION TO SPORULATION TIME SERIES , 1999 .
[34] A. Levin,et al. A nonradioisotope biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue. , 1999, Analytical biochemistry.
[35] M. Napierala,et al. CUG Repeats Present in Myotonin Kinase RNA Form Metastable “Slippery” Hairpins* , 1997, The Journal of Biological Chemistry.
[36] D. Housman,et al. Expansion of a CUG trinucleotide repeat in the 3' untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[37] Ross Ihaka,et al. Gentleman R: R: A language for data analysis and graphics , 1996 .
[38] M. Graham,et al. Quantitation of phosphorothioate oligonucleotides in human plasma. , 1996, Analytical biochemistry.
[39] D. Housman,et al. Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues , 1995, The Journal of cell biology.
[40] P. Berg,et al. Rapid assembly and disassembly of complementary DNA strands through an equilibrium intermediate state mediated by A1 hnRNP protein. , 1992, The Journal of biological chemistry.
[41] David E. Housman,et al. Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member , 1992, Cell.
[42] P. Jong,et al. Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy , 1992, Nature.
[43] David E. Housman,et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy , 1992, Nature.